ClinicalTrials.gg
RecruitingNCT04727424Updated May 8, 2024

Repurposed Approved and Under Development Therapies for Patients With Early-Onset COVID-19 and Mild Symptoms

A Phase 3 interventional study of Spirulin Platensis and Budesonide Powder in Covid19 and SARS-Associated Coronavirus, sponsored by Cardresearch. Recruiting at 12 sites in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-08.

Sponsored by Cardresearch · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2024, 2 years 5 months ago, but the record still lists the study as recruiting.
  • Started Jan 2021; still recruiting 5 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
7,819
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 317 studies in COVID-19 with a site in Brazil — 20 open to participants now, 28 under way, 9 of them phase 3. COVID-19 · Brazil.

Planned enrollment
13th of 263
7,819 · median 205
Started
2021
with 102 others
Phase 3
75 of 317
7 open now
Primary completion
2024-06
later than 15 of 27 live
Registered
166th of 317
by date

Among the 317 studies in COVID-19 with a site in Brazil, this one is the 13th largest by planned enrollment of the 263 interventional ones that give a count, is one of 103 that started in 2021, is one of 75 in phase 3, reaches primary completion later than 15 of the 27 other live ones, and was the 166th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

20 of the 317 studies in COVID-19 with a site in Brazil are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 317 studies in COVID-19 with a site in Brazil, or all of them as a file.
02

Study summary

The COVID-19 pandemic has been characterized by high morbidity and mortality, especially in certain subgroups of patients. To date, no treatment has been shown to be effective in patients with early-onset disease and mild symptoms. Experimental studies have demonstrated a potential anti-inflammatory role of Fluvoxamine, Fluoxetine, Budesonide and Spirulin Platensis in SARS-CoV-2 infections and observational studies have suggested a reduced complications in patients with COVID-19 disease.

Read the detailed description

In December 2019 a series of viral pneumonia cases were reported in the city of Wuhan, China and a new subtype of coronavirus has been identified as the causative agent of this condition. On February 11, 2000 the disease has been characterized as COVID-19 and on March 11 the World Health Organization (WHO) declared a state of worldwide pandemic. On January 25, 2021 there are 98,794,942 cases and 2,124,193 documented deaths (global case-fatality ratio of 2.15%).

To date, no early treatment has been identified as effective in combating this disease which has been identified as with high morbidity and mortality. Epidemiological data suggest that despite development of vaccines we will have hundreds od thousands of cases in the next two years.

Thus, we propose the prospective, double-blinded, randomized evaluation of potential therapies against SARS-CoV2 and some clinical evidence derived from observational studies on reducing complications if used early on the disease, before inflammatory cascade is fully activated.

Important considerations on TOGETHER Adaptive Trial:

  1. The Pegylated Lambda interferon arm was ended on early February 2022.
  2. The Proposal of a new arm: Spirulin platensis.
  3. The Modification on primary endpoints that will be effective only for new arms added to the trial (Spirulin platensis).
03

Conditions studied

  • Covid19
  • SARS-Associated Coronavirus

Keywords

  • COVID-19
  • Randomized study
  • Fluvoxamine
  • Budesonide
  • Fluoxetine
  • Spirulin Platensis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

A - Inclusion Criteria (except fluoxetine + budesonide and paracetamol arms):

  1. Patients over 18 years old with the ability to provide free and
  2. Acute Flu-Like symptoms \< 07 days.
  3. Patients with at least ONE enhancement criteria:

    1. The. Age > 50 years old (does not need any of the other criteria)
    2. Diabetes mellitus requiring oral medication or insulin
    3. Systemic arterial hypertension requiring at least 01 oral medication for treatment
    4. Known cardiovascular diseases (heart failure, congenital heart disease, valvular disease, coronary artery disease, cardiomyopathies under treatment, clinically manifest heart diseases with clinical repercussions)
    5. Symptomatic and/or treated lung disease (emphysema, fibrosing diseases)
    6. Patients with symptomatic asthma requiring chronic use of agents to control symptoms.
    7. Obesity, defined as > 30 kg/m2 in weight and height information provided by the patient;
    8. Transplant patients
    9. Patient with stage IV chronic kidney disease or on dialysis.
    10. Patient with temperature measured at screening > 38º C.
    11. Patients with at least one of the following symptoms: Cough, Dyspnea, Ventilator-dependent chest pain or myalgias with limitation of daily activities (Criterion limited to 25% of randomizations)
    12. patients/using therapy (equivalent to a maximum of 10 mg of prednisone per day) and/or immunosuppressive therapy)
    13. Patients with a history of cancer in the last 5 years or currently undergoing oncological treatment
  4. Patient with positive rapid test for SARS-CoV2 antigen performed on occasion of the screening or patient with a positive SARS-CoV2 diagnostic test within 07 days of the onset of symptoms.
  5. Willingness to use the proposed investigative treatment and follow the protocol-related procedures foreseen in the research.
  6. Signing the Free and Informed Consent Form before any research procedures

B - Inclusion criteria for the Fluoxetine + Budesonide combination arm (07 days of treatment - partnership with the "ANTICOV Consortium"):

  1. Patients over 18 years of age with the ability to provide free and informed consent.
  2. Patients treated at a Basic Health Unit of the Unified Health System (SUS) or patients treated at emergency care units of the SUS or supplementary medicine with an acute clinical condition compatible with COVID 19.
  3. Patients over 18 years of age and a history of at least ONE of the following criteria.

    1. Diabetes mellitus, heart disease, chronic kidney disease, , cerebrovascular diseases or patients considered to be underweight or overweight according to the investigator's judgment (BMI ≤ 16 or BMI > 25).

      OR

    2. Individuals aged ≥ 60 years without co-morbidities.

      1. COVID-19 confirmed by molecular or antigenic test for SARS-CoV-2 within up to 24 hours prior to screening and a maximum of 2 days after sample collection.
      1. Viral syndrome with or without pneumonia and arterial O2 saturation > 94%.
      1. Signing the Free and Informed Consent Form before any research procedures.
      1. Willingness to use the proposed treatment and follow the procedures provided for in the research.

Exclusion Criteria:

  1. Negative diagnostic test for SARS-CoV2 associated with acute flu-like symptoms (patients with a negative test taken early and becoming positive a few days later are eligible, as long as they are \< 07 days from the onset of flu-like symptoms);
  2. Patients with an acute respiratory condition compatible with COVID-19 treated in the primary care network and with a decision to be hospitalized;
  3. Patients with acute respiratory symptoms due to other causes;
  4. Dyspnea secondary to other acute and chronic respiratory causes or infections (e.g. decompensated COPD, Acute bronchitis, Pneumonia other than viral, Primary pulmonary arterial hypertension);
  5. Patients requiring hospitalization due to COVID-19 or SpO2 ≤ 93%.
  6. Exclusion criteria applicable to the 7-day treatment arms:

    1. Abnormal findings on physical examination: Respiratory rate ≥ 25 irm; blood pressure \< 90/ 60 mmHg or > 160/ 100 mmHg; Weight \< 45 kg; recent episodes of vomiting in the last 24 hours or diarrhea > 3 episodes in the last 24 hours or serum potassium below 3.5 mEq/L.
    2. Serious injury to any organ that requires resuscitation and continuous treatment.
    3. Use of chronic systemic corticosteroid therapy with prednisone equivalent doses of > 40 mg/day
    4. Ongoing immunosuppressive treatment
    5. History of known pulmonary arterial hypertension or pulmonary fibrosis
    6. Patients previously vaccinated with two doses for SARS-CoV-2, with the last dose administered less than 180 days after screening; Patients with a single dose of Janssen SARS-CoV-2 vaccine received (except Janssen vaccine) and unvaccinated patients can participate regardless of the period.
    7. Use of serotonin reuptake inhibitors (all)
    8. Patients vaccinated for SARS-CoV-2 (complete vaccination - 02 doses) within 06 months of the last dose before randomization or patients who received a "booster" dose at any time before randomization.
    9. For any new antiviral included in the study, prior treatment with the antiviral, presence of to its use or concomitant intake of medication prohibited for its use.
    10. Enrolled in other clinical trials with unregistered medicines or with a registered medicine that may interact with any of the study PIs or contraindicated as concomitant treatment in the last 3 months before screening.
  7. Exclusion criteria applicable to the 10-day treatment arm:

    A. Chronic use of serotonin reuptake inhibitors other than sertraline B. Chronic use of corticosteroid therapy with prednisone equivalent doses of > 40 mg/day

  8. Exclusion criteria applicable to the 14-day treatment arm: Patients with phenylketonuria;
  9. Continued use of monoamine oxidation inhibitors (MAOIs): Phenelzine, Tranylcypromine, Selegiline, Isocarboxazid, moclobemide;
  10. Patients with severe psychiatric disorders - schizophrenia, uncontrolled bipolar disorders, major depression with suicidal ideation.
  11. Pregnant or breastfeeding patients;
  12. History of severe ventricular cardiac arrhythmia (Ventricular Tachycardia, recovered ventricular fibrillation patients) or Long Syndrome;
  13. Known history of decompensated heart failure ( III or IV), recent myocardial infarction (event \< 90 days from screening), unstable angina, recent coronary bypass surgery (procedure \< 90 days from screening), recent stroke ( event \< 90 days from screening), symptomatic carotid disease, or mitral or aortic stenosis of moderate to severe intensity;
  14. Surgical procedure or hospitalization planned (for other indications) to occur during treatment or up to 5 days after the last dose of study medication;
  15. Current daily and/or uncontrolled alcohol consumption, which in the investigator's view could compromise participation in the study;
  16. History of seizures in the last month or uncontrolled seizures;
  17. Clinical history of moderate to severe hepatic impairment or liver cirrhosis with classification C;
  18. Patients with known severe degenerative neurological diseases and/or serious mental illnesses as assessed by the investigator;
  19. Inability of the patient or representative to give consent or adhere to the procedures proposed in the protocol;
  20. Any clinical conditions, including psychiatric conditions, which in the investigator's view could be an impediment to the use of research medications;
  21. Known and/or intolerance to Spirulin Platensis, Budesonide, Fluvoxamine and Fluoxetine;
  22. Use of medications which have a known interaction with Spirulin platensis, Budesonide, Fluvoxamine and Fluoxetine;
  23. Inability to use the medications and formulations provided for in this research;
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
7,819 participants (estimated)

Study arms

  • Active comparator
    Fluvoxamine Maleate + Budesonide Inhalation powder

    Fluvoxamine 100 mg oral tablets: One tablet after randomization (Day 0) followed by 100 mg BID for the following 09 days PLUS Budesonide Inhalation powder 400 mcg capsule: One 400 mcg capsule (inhalation) after randomization (Day 0) followed by one puff of 400 mcg BID for the following 09 days

    Drug: Budesonide Powder · Drug: Placebo

  • Active comparator
    Spirulin Platensis

    Spirulin Platensis 500mg oral tablets Two tablets right after randomization (day 0) followed by 1.000mg (two tablets) BID for the following 10 days.

    Dietary Supplement: Spirulin Platensis · Drug: Placebo

  • Active comparator
    Fluoxetine + Budesonide Inhalation powder

    Fluoxetine 20 mg oral tablets: Two tablets right after randomization (Day 0) followed by 40 mg MID for the following 06 days PLUS Budesonide Inhalation powder 400 mcg capsule: One 400 mcg capsule (inhalation) right after randomization (Day 0) followed by one puff of 400 mcg BID for the following 06 days

    Drug: Fluoxetine 20 MG · Drug: Placebo

  • Placebo comparator
    Placebo

    Placebo oral tablets (10-day schedule): Matching tablets started after randomization using the dosing regimen of 01 tablet every 12 hs starting at Randomization Day (Day 0) until end of Day 09 (total of 10 day schedule) PLUS Placebo Inhalation Therapy: One dosing (inhalation puff) right after randomization (Day 0) followed by one puff BID for the following 09 days OR Paracetamol (07-day schedule - active comparator): Paracetamol 500 mg tablets started after randomization using the dosing regimen of 01 tablet BID starting at Rand. Day (Day 0) until end of Day 06 (total of 07 days schedule - ANTICOV Arm) OR Matching tablets started after randomization using the dosing regimen of 02 tablets every 12 hs starting at Randomization Day (Day 0) until end of Day 09 (total of 10 day schedule)

    Dietary Supplement: Spirulin Platensis · Drug: Budesonide Powder · Drug: Fluoxetine 20 MG

Interventions

  • Dietary supplementSpirulin Platensis

    Two tablets every 12 hours since randomization through day 09 following randomization

  • DrugBudesonideStudies of BudesonideBudesonide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    One Fluvoxamine tablet every 12 hours since randomization through day 09. PLUS 01 Budesonide powder (inhalation) every 12 hours since randomization through day 09.

    Also known as: Fluvoxamine Maleate 100 MG [Luvox]

  • DrugFluoxetineStudies of FluoxetineFluoxetine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Two Fluoxetine tablets every day starting just after randomization through day 07. PLUS 01 Budesonide powder (inhalation) every 12 hours since randomization through day 07.

    Also known as: Budesonide powder

  • DrugPlacebo

    Placebo oral tablets (10-day schedule): Matching tablets started after randomization using the dosing regimen of 01 tablet every 12 hs starting at Randomization Day (Day 0) until end of Day 09 (total of 10 day schedule) PLUS Placebo Inhalation Therapy: One dosing (inhalation puff) right after randomization (Day 0) followed by one puff BID for the following 09 days OR Paracetamol (07-day schedule - active comparator): Paracetamol 500 mg tablets started after randomization using the dosing regimen of 01 tablet BID starting at Rand. Day (Day 0) until end of Day 06 (total of 07 days schedule - ANTICOV Arm) OR Matching tablets started after randomization using the dosing regimen of 02 tablets every 12 hs starting at Randomization Day (Day 0) until end of Day 09 (total of 10 day schedule)

06

What researchers measure

Primary outcomes

  1. Rate of fluvoxamine + budesonide, fluoxetine + budesonide, Spirulin platensis in emergency care visits due to the worsening of COVID-19;

    Evaluation of emergency visits due to progression of COVID-19 symptoms and/or ocmplications

    Time frame: 28 days

  2. Rate of fluvoxamine + budesonide, fluoxetine + budesonide, Spirulin platensis in changing the need for Hospitalization due to COVID-19 progression and related complications, including lower respiratory tract infection (LRTI)

    Hospitalization due to COVID-19 progression and related complications

    Time frame: 28 days

  3. Rate of fluvoxamine + budesonide, fluoxetine + budesonide, Spirulin platensis in changing SPO2 ≤ 93% after randomization

    Reduction of SPO2 ≤ 93% after randomization

    Time frame: 28 days

Secondary outcomes

  1. Time to clinical changes (up to 28 days of randomization), defined as greater than 50% symptoms changing in reference to baseline symptoms.

    time to \> 50% clinical symptoms changes as reported on baseline visit (self reported)

    Time frame: Randomization through day 28

  2. Time to clinical failure, defined as time to need for hospitalization due to the clinical progression of COVID-19 or associated complications.

    Time to hospitalization

    Time frame: Randomization through day 28

  3. Number of days with respiratory symptoms since randomization

    Days with symptoms

    Time frame: Randomization through day 28

  4. Rate of all-cause hospitalizations

    All cause hospitalizations

    Time frame: Randomization through day 28

  5. Rate of COVID-19 related hospitalizations

    COVID-19 hospitalizations

    Time frame: Randomization through day 28

  6. Number of days on Mechanical Ventilator

    Number of days on mechanical Ventilator

    Time frame: Randomization through day 28

  7. Number of Days on Intensive Care Unit

    Number of days on Intensive Care Unit

    Time frame: Randomization through day 28

  8. Number of days on hospitalizations

    Number of days on Hospitalization

    Time frame: Randomization through day 28

  9. Health and Functioning after COVID-19 disease

    Self evaluation of health functioning post COVID using Promis Global Health Score. Short term scale is a 10 item patient-reported questionnaire using response options as a 5-point and one 11 point rating scale. Higher scores means better global health.

    Time frame: Day 14 and Day 28

  10. Numbers of days with respiratory symptoms on WURSS-21 scale after randomization

    Numbers of days with respiratory symptoms on WURSS-21 scale after randomization

    Time frame: Randomization through day 28

  11. Time to symptom resolution

    Time to improvement \> 50% of baseline symptomatology based on WURSS-21 Scale.

    Time frame: randomization through day 28

  12. Adherence of Study drug

    Percentage of adherence on Study drug

    Time frame: Randomization through day 10

07

Study locations

11 of 12 sites recruiting
  • City of Betim
    Betim, MG 32550770, Brazil
    Recruiting
    • Daniela C Medeiros, MD,PhD · Contact
    • Tainara S Vieira · Contact
  • Hospital e Maternidade Santa Rita
    Contagem, MG 32215000, Brazil
    Recruiting
    • Thiago S Ferreira, MD · Contact
  • City of Governador Valadares
    Governador Valadares, MG 35010-000, Brazil
    Recruiting
    • Adhemar DF Neto, MD, PhD · Contact
    • Marina L Marques, SC · Contact
  • City of Ibirité
    Ibirité, MG 30240528, Brazil
    Recruiting
  • City of Nova Lima
    Nova Lima, MG 34000000, Brazil
    Recruiting
    • Leticia F Costa, RN · Contact
    • Rosemary M Silva · Contact
  • City of Santa Luzia
    Santa Luzia, MG 33105160, Brazil
    Recruiting
    • Eduardo Augusto SM Silva, MD, PhD · Contact
    • Vitoria HS Campos, SC · Contact
  • City of Sete Lagoas
    Sete Lagoas, MG 35700-000, Brazil
    Recruiting
  • CARDRESEARCH - Cardiologia Assistencial e de Pesquisa
    Belo Horizonte, Minas Gerais 30150240, Brazil
    Recruiting
  • City of Brumadinho
    Brumadinho, Minas Gerais 35.460-000, Brazil
    Not yet recruiting
    • Eduardo D Calegari, MD · Contact
    • Eduardo Calegari, MD · Principal investigator
  • City of Igarapé
    Igarapé, Minas Gerais 32900-000, Brazil
    Recruiting
    • Luciene B Ribeiro, RN · Contact+55313657574
  • Centro Universitário FIPMOC
    Montes Claros, Minas Gerais 39.408-007, Brazil
    Recruiting
    • Ana Maria, MD · Contact
    • Ana Maria R Nogueira, MD · Principal investigator
    • Ana Paula FG Alvarenga, MD · Sub investigator
  • Universidade Federal de Ouro Preto
    Ouro Preto, Minas Gerais 35400000, Brazil
    Recruiting
    • Leonardo CM Savassi, MD, PhD · Contactleosavassi@gmail.com
    • Leonardo Savassi, MD, PhD · Principal investigator
08

References and documents

Publications

  • Rayner CR, Dron L, Park JJH, Decloedt EH, Cotton MF, Niranjan V, Smith PF, Dodds MG, Brown F, Reis G, Wesche D, Mills EJ. Accelerating Clinical Evaluation of Repurposed Combination Therapies for COVID-19. Am J Trop Med Hyg. 2020 Oct;103(4):1364-1366. doi: 10.4269/ajtmh.20-0995. PubMed 32828137 ↗
  • Park JJH, Mogg R, Smith GE, Nakimuli-Mpungu E, Jehan F, Rayner CR, Condo J, Decloedt EH, Nachega JB, Reis G, Mills EJ. How COVID-19 has fundamentally changed clinical research in global health. Lancet Glob Health. 2021 May;9(5):e711-e720. doi: 10.1016/S2214-109X(20)30542-8. PubMed 33865476 ↗
  • Forrest JI, Rawat A, Duailibe F, Guo CM, Sprague S, McKay P, Reis G, Mills EJ. Resilient Clinical Trial Infrastructure in Response to the COVID-19 Pandemic: Lessons Learned from the TOGETHER Randomized Platform Clinical Trial. Am J Trop Med Hyg. 2022 Jan 7;106(2):389-393. doi: 10.4269/ajtmh.21-1202. PubMed 34996047 ↗
  • Reis G, Mills E. Fluvoxamine for the treatment of COVID-19 - Author's reply. Lancet Glob Health. 2022 Mar;10(3):e333. doi: 10.1016/S2214-109X(21)00588-X. No abstract available. PubMed 35180413 ↗
  • Thorlund K, Sheldrick K, Mills E. Molnupiravir for Covid-19 in Nonhospitalized Patients. N Engl J Med. 2022 Mar 31;386(13):e32. doi: 10.1056/NEJMc2201612. Epub 2022 Mar 16. No abstract available. PubMed 35294804 ↗
  • Park JJH, Detry MA, Murthy S, Guyatt G, Mills EJ. How to Use and Interpret the Results of a Platform Trial: Users' Guide to the Medical Literature. JAMA. 2022 Jan 4;327(1):67-74. doi: 10.1001/jama.2021.22507. PubMed 34982138 ↗
  • Jhuti D, Rawat A, Guo CM, Wilson LA, Mills EJ, Forrest JI. Interferon Treatments for SARS-CoV-2: Challenges and Opportunities. Infect Dis Ther. 2022 Jun;11(3):953-972. doi: 10.1007/s40121-022-00633-9. Epub 2022 Apr 21. PubMed 35445964 ↗
  • Park JJH, Dron L, Mills EJ. Moving forward in clinical research with master protocols. Contemp Clin Trials. 2021 Jul;106:106438. doi: 10.1016/j.cct.2021.106438. Epub 2021 May 14. PubMed 34000408 ↗
  • Park JJH, Ford N, Xavier D, Ashorn P, Grais RF, Bhutta ZA, Goossens H, Thorlund K, Socias ME, Mills EJ. Randomised trials at the level of the individual. Lancet Glob Health. 2021 May;9(5):e691-e700. doi: 10.1016/S2214-109X(20)30540-4. PubMed 33865474 ↗
  • Lee Z, Rayner CR, Forrest JI, Nachega JB, Senchaudhuri E, Mills EJ. The Rise and Fall of Hydroxychloroquine for the Treatment and Prevention of COVID-19. Am J Trop Med Hyg. 2021 Jan;104(1):35-38. doi: 10.4269/ajtmh.20-1320. PubMed 33236703 ↗
  • Dron L, Dillman A, Zoratti MJ, Haggstrom J, Mills EJ, Park JJH. Clinical Trial Data Sharing for COVID-19-Related Research. J Med Internet Res. 2021 Mar 12;23(3):e26718. doi: 10.2196/26718. PubMed 33684053 ↗
  • Dillman A, Park JJH, Zoratti MJ, Zannat NE, Lee Z, Dron L, Hsu G, Smith G, Khakabimamaghani S, Harari O, Thorlund K, Mills EJ. Reporting and design of randomized controlled trials for COVID-19: A systematic review. Contemp Clin Trials. 2021 Feb;101:106239. doi: 10.1016/j.cct.2020.106239. Epub 2020 Dec 3. PubMed 33279656 ↗
  • Reis G, Dos Santos Moreira-Silva EA, Silva DCM, Thabane L, Milagres AC, Ferreira TS, Dos Santos CVQ, de Souza Campos VH, Nogueira AMR, de Almeida APFG, Callegari ED, de Figueiredo Neto AD, Savassi LCM, Simplicio MIC, Ribeiro LB, Oliveira R, Harari O, Forrest JI, Ruton H, Sprague S, McKay P, Glushchenko AV, Rayner CR, Lenze EJ, Reiersen AM, Guyatt GH, Mills EJ; TOGETHER investigators. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob Health. 2022 Jan;10(1):e42-e51. doi: 10.1016/S2214-109X(21)00448-4. Epub 2021 Oct 28. Erratum In: Lancet Glob Health. 2022 Apr;10(4):e481. doi: 10.1016/S2214-109X(22)00081-X. Lancet Glob Health. 2022 Sep;10(9):e1246. doi: 10.1016/S2214-109X(22)00336-9. PubMed 34717820 ↗
  • Reis G, Dos Santos Moreira Silva EA, Medeiros Silva DC, Thabane L, Cruz Milagres A, Ferreira TS, Quirino Dos Santos CV, de Figueiredo Neto AD, Diniz Callegari E, Monteiro Savassi LC, Campos Simplicio MI, Barra Ribeiro L, Oliveira R, Harari O, Bailey H, Forrest JI, Glushchenko A, Sprague S, McKay P, Rayner CR, Ruton H, Guyatt GH, Mills EJ. Effect of early treatment with metformin on risk of emergency care and hospitalization among patients with COVID-19: The TOGETHER randomized platform clinical trial. Lancet Reg Health Am. 2022 Feb;6:100142. doi: 10.1016/j.lana.2021.100142. Epub 2021 Dec 14. PubMed 34927127 ↗
  • Reis G, Silva EASM, Silva DCM, Thabane L, Milagres AC, Ferreira TS, Dos Santos CVQ, Campos VHS, Nogueira AMR, de Almeida APFG, Callegari ED, Neto ADF, Savassi LCM, Simplicio MIC, Ribeiro LB, Oliveira R, Harari O, Forrest JI, Ruton H, Sprague S, McKay P, Guo CM, Rowland-Yeo K, Guyatt GH, Boulware DR, Rayner CR, Mills EJ; TOGETHER Investigators. Effect of Early Treatment with Ivermectin among Patients with Covid-19. N Engl J Med. 2022 May 5;386(18):1721-1731. doi: 10.1056/NEJMoa2115869. Epub 2022 Mar 30. PubMed 35353979 ↗
  • Reis G, Moreira Silva EAS, Medeiros Silva DC, Thabane L, Campos VHS, Ferreira TS, Santos CVQ, Nogueira AMR, Almeida APFG, Savassi LCM, Figueiredo-Neto AD, Dias ACF, Freire Junior AM, Bitaraes C, Milagres AC, Callegari ED, Simplicio MIC, Ribeiro LB, Oliveira R, Harari O, Wilson LA, Forrest JI, Ruton H, Sprague S, McKay P, Guo CM, Limbrick-Oldfield EH, Kanters S, Guyatt GH, Rayner CR, Kandel C, Biondi MJ, Kozak R, Hansen B, Zahoor MA, Arora P, Hislop C, Choong I, Feld JJ, Mills EJ, Glenn JS; TOGETHER Investigators. Early Treatment with Pegylated Interferon Lambda for Covid-19. N Engl J Med. 2023 Feb 9;388(6):518-528. doi: 10.1056/NEJMoa2209760. PubMed 36780676 ↗
  • Reis G, Mills EJ, Glenn JS. Pegylated Interferon Lambda for Covid-19. Reply. N Engl J Med. 2023 Jun 1;388(22):2108. doi: 10.1056/NEJMc2303519. No abstract available. PubMed 37256990 ↗
  • Reis G, Mills EJ. Ivermectin Treatment for Covid-19. Reply. N Engl J Med. 2022 Dec 15;387(24):e66. doi: 10.1056/NEJMc2207995. No abstract available. PubMed 36516104 ↗

Individual participant data

Plan to share: Yes — Patient tables and main data.

Supporting information: Statistical analysis plan

Time frame: As of protocol termination

Access criteria: Upon request

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2021 (actual). Primary completion is estimated for Jun 2024, 40 months after the start.

Of 285 non-industry phase 3 interventional studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's planned 40 months is above that.

Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2021
First posted
Jan 27, 2021
StartActual
Jan 19, 2021
Primary completionEst.
Jun 1, 2024
CompletionEst.
Jul 1, 2024
Last update
May 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04727424
Lead sponsor
Cardresearch
Collaborators
Cytel Inc., McMaster University, Fastgrants, Eiger BioPharmaceuticals, RainWater Foundation
Responsible party
Sponsor
First posted
Jan 27, 2021
Start date
Jan 19, 2021
Primary completion
Jun 1, 2024 (estimated)
Completion
Jul 1, 2024 (estimated)
Last update
May 8, 2024

Study contacts

Gilmar Reis, MD, PhD
Contact
administrador@cardresearch.org
+553132416574
Eduardo Santos, MD, PhD
Contact
duduaugusto1@yahoo.com.br
+553132416574
Gilmar Reis, MD,PhD.
study chair · Cardresearch - Cardiologia Assistencial e de Pesquisa
Edward J Mills, FRCP
study director · McMaster University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion